Theravance Biopharma, Inc. reported an insider sale on March 16, 2026, when Rhonda Farnum, the company’s Senior Vice President of Communications and Medical Affairs, sold 31,067 ordinary shares for a total of approximately $433,637. The disposition occurred across three separate transactions at prices ranging from $13.9162 to $14.00 per share.
Following the sales, Farnum retained direct ownership of 232,699 shares of Theravance Biopharma. The transactions were carried out pursuant to a 10b5-1 trading plan dated September 3, 2025.
The insider activity coincides with current market levels in which TBPH is trading at $13.83. The stock has produced a 50% return over the past 12 months, while showing a 26% decline year-to-date. An analysis on the platform indicates the stock appears overvalued relative to its Fair Value and places it on the Most Overvalued list. Investors seeking deeper proprietary research may access extended pro research reports covering TBPH and more than 1,400 U.S. equities.
Program setback and corporate response
Theravance also disclosed that its Phase 3 CYPRESS clinical study for ampreloxetine failed to meet the trial’s primary endpoint. The study, which evaluated ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy, did not achieve statistical significance on the Orthostatic Hypotension Symptom Assessment composite score.
In response to the negative trial outcome, Theravance has elected to wind down the ampreloxetine program. The company plans a substantial reduction in operating expenses - approximately 60%, or about $70 million. This restructuring will eliminate the research and development function and produce significant cuts to general and administrative staff, affecting roughly half of the company’s workforce.
Analyst reactions
- Oppenheimer downgraded the stock from Outperform to Perform, citing insufficient data to support an application for New Drug Approval.
- B. Riley lowered its rating from Buy to Neutral and reduced its price target from $28 to $14.
- BTIG trimmed its price target from $40 to $21 while keeping a Buy rating; analyst Julian Harrison removed ampreloxetine from BTIG’s financial model.
These moves by major research firms reflect the immediate market response to the trial failure and the company’s decision to wind down the program.
Context for investors
The insider sale, executed under a 10b5-1 plan, and the simultaneous operational retrenchment underscore a period of transition for Theravance Biopharma. The company is moving away from development of ampreloxetine and significantly shrinking its cost base, while analysts revise expectations and pricing assumptions to reflect the changed outlook.
Information about insider holdings, transaction details, corporate restructuring, and analyst coverage provides investors with a consolidated view of recent developments. The company’s forthcoming disclosures and execution of its restructuring plan will determine the near-term operating profile and cash-flow dynamics.